文献速递中毒与环境急症消化、代谢与肾脏急症

COVID-19 大流行前后丁丙诺啡相关过量死亡的趋势与特征

Trends and Characteristics of Buprenorphine-Involved Overdose Deaths Prior to and During the COVID-19 Pandemic.
PubMed 文献 · JAMA Netw Open · 2023-01-03
一句话结论2020年COVID-19大流行期间美国放宽丁丙诺啡处方并未增加丁丙诺啡相关过量死亡比例,但丁丙诺啡相关死亡中92.7%合并至少一种其他药物。

该横断面研究利用州非故意药物过量报告系统(SUDORS)数据,分析2019年7月至2021年6月46个州及哥伦比亚特区共89111例药物过量死亡,其中阿片类相关74474例,丁丙诺啡相关1955例。丁丙诺啡相关死亡占全部药物过量死亡的2.2%、阿片类相关死亡的2.6%。月度阿片类过量死亡增加,但丁丙诺啡相关比例波动未上升。丁丙诺啡相关死亡者中92.7%合并至少一种其他药物,合并非法制造芬太尼比例50.2%低于其他阿片类死亡的85.3%。结论认为放宽丁丙诺啡处方获取未伴随丁丙诺啡相关死亡比例增加,但需扩大公平可及的丁丙诺啡治疗。

要点

  • 2019年7月至2021年6月,46个州及哥伦比亚特区报告89111例药物过量死亡,其中阿片类相关74474例,丁丙诺啡相关1955例(占全部药物过量死亡2.2%、阿片类相关死亡2.6%)。
  • 丁丙诺啡相关死亡者中92.7%(95%CI 91.5%-93.7%)合并至少一种其他药物,合并抗惊厥药比例18.6%(95%CI 17.0%-20.3%)高于其他阿片类相关死亡的5.4%(95%CI 5.2%-5.5%)。
  • 丁丙诺啡相关死亡合并非法制造芬太尼比例50.2%(95%CI 48.1%-52.3%),低于其他阿片类相关死亡的85.3%(95%CI 85.1%-85.5%)。
  • 丁丙诺啡相关死亡者中女性占36.1%(95%CI 34.2%-38.2%),非西班牙裔白人占86.1%(95%CI 84.6%-87.6%),农村地区居民占20.8%(95%CI 19.1%-22.5%),均高于其他阿片类相关死亡者。
  • 月度阿片类过量死亡增加,但丁丙诺啡相关比例虽有波动但未上升;丁丙诺啡相关死亡者接受心理健康治疗比例31.4%(95%CI 29.3%-33.5%)高于其他阿片类相关死亡的13.3%(95%CI 13.1%-13.6%)。

适用人群与场景

  • 2019年7月至2021年6月美国46个州及哥伦比亚特区的药物过量死亡者,数据来自州非故意药物过量报告系统(SUDORS)。
  • 分析对象包括丁丙诺啡相关过量死亡者和其他阿片类相关过量死亡者。

研究设计与关键结果

  • 研究类型:横断面研究;数据来源:州非故意药物过量报告系统(SUDORS),覆盖46个州及哥伦比亚特区;时间范围:2019年7月至2021年6月;数据分析时间:2022年3月7日至2022年6月30日。
  • 共报告89111例药物过量死亡,其中阿片类相关74474例,丁丙诺啡相关1955例;丁丙诺啡相关死亡占全部药物过量死亡的2.2%、占阿片类相关死亡的2.6%。
  • 丁丙诺啡相关死亡者中位年龄41岁(IQR 34-55),其他阿片类相关死亡者中位年龄40岁(IQR 31-52)。
  • 丁丙诺啡相关死亡者中女性占36.1%(95%CI 34.2%-38.2%),其他阿片类相关死亡者中女性占29.1%(95%CI 28.8%-29.4%)。
  • 丁丙诺啡相关死亡者中非西班牙裔白人占86.1%(95%CI 84.6%-87.6%),其他阿片类相关死亡者中占69.4%(95%CI 69.1%-69.7%)。
  • 丁丙诺啡相关死亡者中农村地区居民占20.8%(95%CI 19.1%-22.5%),其他阿片类相关死亡者中占11.4%(95%CI 11.2%-11.7%)。
  • 丁丙诺啡相关死亡者中合并至少一种其他药物者占92.7%(95%CI 91.5%-93.7%);合并抗惊厥药者占18.6%(95%CI 17.0%-20.3%),其他阿片类相关死亡者中占5.4%(95%CI 5.2%-5.5%);合并非法制造芬太尼者占50.2%(95%CI 48.1%-52.3%),其他阿片类相关死亡者中占85.3%(95%CI 85.1%-85.5%)。
  • 丁丙诺啡相关死亡者接受心理健康治疗者占31.4%(95%CI 29.3%-33.5%),其他阿片类相关死亡者中占13.3%(95%CI 13.1%-13.6%)。

证据类型、等级与局限

  • 证据类型:横断面研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 研究提示,COVID-19大流行期间为促进丁丙诺啡治疗可及性所采取的行动,与丁丙诺啡相关过量死亡比例增加无关。
  • 作者认为,需要努力扩大更公平且具有文化胜任力的丁丙诺啡治疗可及性与提供。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Buprenorphine remains underused in treating opioid use disorder, despite its effectiveness. During the onset of the COVID-19 pandemic, the US government implemented prescribing flexibilities to support continued access.

OBJECTIVE: To determine whether buprenorphine-involved overdose deaths changed after implementing these policy changes and highlight characteristics and circumstances of these deaths.

DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study used data from the State Unintentional Drug Overdose Reporting System (SUDORS) to assess overdose deaths in 46 states and the District of Columbia occurring July 2019 to June 2021. Data were analyzed from March 7, 2022, to June 30, 2022.

MAIN OUTCOMES AND MEASURES: Buprenorphine-involved and other opioid-involved overdose deaths were examined. Monthly opioid-involved overdose deaths and the percentage involving buprenorphine were computed to assess trends. Proportions and exact 95% CIs of drug coinvolvement, demographics, and circumstances were calculated by group.

RESULTS: During July 2019 to June 2021, 32 jurisdictions reported 89 111 total overdose deaths and 74 474 opioid-involved overdose deaths, including 1955 buprenorphine-involved overdose deaths, accounting for 2.2% of all drug overdose deaths and 2.6% of opioid-involved overdose deaths. Median (IQR) age was similar for buprenorphine-involved overdose deaths (41 [34-55] years) and other opioid-involved overdose deaths (40 [31-52] years). A higher proportion of buprenorphine-involved overdose decedents, compared with other opioid-involved decedents, were female (36.1% [95% CI, 34.2%-38.2%] vs 29.1% [95% CI, 28.8%-29.4%]), non-Hispanic White (86.1% [95% CI, 84.6%-87.6%] vs 69.4% [95% CI, 69.1%-69.7%]), and residing in rural areas (20.8% [95% CI, 19.1%-22.5%] vs 11.4% [95% CI, 11.2%-11.7%]). Although monthly opioid-involved overdose deaths increased, the proportion involving buprenorphine fluctuated but did not increase during July 2019 to June 2021. Nearly all (92.7% [95% CI, 91.5%-93.7%]) buprenorphine-involved overdose deaths involved at least 1 other drug; higher proportions involved other prescription medications compared with other opioid-involved overdose deaths (eg, anticonvulsants: 18.6% [95% CI, 17.0%-20.3%] vs 5.4% [95% CI, 5.2%-5.5%]) and a lower proportion involved illicitly manufactured fentanyls (50.2% [95% CI, 48.1%-52.3%] vs 85.3% [95% CI, 85.1%-85.5%]). Buprenorphine decedents were more likely to be receiving mental health treatment than other opioid-involved overdose decedents (31.4% [95% CI, 29.3%-33.5%] vs 13.3% [95% CI, 13.1%-13.6%]).

CONCLUSIONS AND RELEVANCE: The findings of this cross-sectional study suggest that actions to facilitate access to buprenorphine-based treatment for opioid use disorder during the COVID-19 pandemic were not associated with an increased proportion of overdose deaths involving buprenorphine. Efforts are needed to expand more equitable and culturally competent access to and provision of buprenorphine-based treatment.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Tanz LJ, Jones CM, Davis NL, et al. Trends and Characteristics of Buprenorphine-Involved Overdose Deaths Prior to and During the COVID-19 Pandemic. JAMA Netw Open. 2023. PMID: 36662523. doi:10.1001/jamanetworkopen.2022.51856

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。